Compare · BCYC vs NVO
BCYC vs NVO
Side-by-side comparison of Bicycle Therapeutics plc (BCYC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCYC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 758.1x BCYC ($293.9M).
- Over the past year, BCYC is down 49.3% and NVO is down 22.5% - NVO leads by 26.7 points.
- BCYC has been more active in the news (9 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for BCYC).
- Company
- Bicycle Therapeutics plc
- Novo Nordisk A/S
- Price
- $4.21+0.48%
- $50.31-2.25%
- Market cap
- $293.9M
- $222.81B
- 1M return
- +4.60%
- +15.47%
- 1Y return
- -49.28%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 9
- 4
- Recent ratings
- 20
- 25
Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BCYC
- SEC Form 4 filed by Chief Financial Officer Thompson Travis Alvin
- SEC Form 4 filed by CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguson
- SEC Form 4 filed by Chief Operating Officer Perry Jennifer Scott
- SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Skynner Michael
- Chief Operating Officer Perry Jennifer Scott sold $6,054 worth of Ordinary Shares (1,412 units at $4.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 91,052 units (SEC Form 4) to cover taxes
- Chief Financial Officer Thompson Travis Alvin sold $3,945 worth of Ordinary Shares (923 units at $4.27), decreasing direct ownership by 1% to 64,441 units (SEC Form 4) (tax liability)
- CHIEF SCIENTIFIC OFFICER Skynner Michael sold $10,231 worth of Ordinary Shares (2,391 units at $4.28), decreasing direct ownership by 1% to 157,171 units (SEC Form 4) (tax withholding)
- CHIEF EXECUTIVE OFFICER Lee Kevin sold $32,701 worth of Ordinary Shares (7,642 units at $4.28), decreasing direct ownership by 1% to 603,671 units (SEC Form 4) (for tax liability)
- CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguson sold $7,530 worth of Ordinary Shares (1,761 units at $4.28), decreasing direct ownership by 2% to 94,375 units (SEC Form 4) (withholding obligation)
- Bicycle Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S